Navigation Links
Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis

AUSTIN, Texas and KOLN, Germany, June 8, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG® Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection.  This includes the detection of hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain responsible for the current outbreak.


Kliniken der Stadt Koln Institut fur Pathologie worked with Luminex last week to quickly implement this new diagnostic assay when they successfully showed xTAG GPP was able to accurately detect the outbreak pathogens in patient samples.

As of 7 June at 15:00 CET World Health Organization (WHO) reported 2,745 people in 12 European countries have been sickened by E. coli.  Since the beginning of May, there have been 722 notified cases of HUS and 25 deaths – nineteen fatalities resulting from HUS infections and six fatalities from E. coli non-HUS infections.  Staff at Kliniken der Stadt Koln Institut fur Pathologie, who use the Luminex xTAG Respiratory Viral Panel (RVP), have quickly adopted xTAG GPP as an important first line screen to help manage the current outbreak in Germany.

Since xTAG GPP can rapidly and simultaneously identify 95% of acute gastroenteritis pathogens, infected patients can be quickly identified and appropriately managed. Positive STEC patients can be closely monitored and treated in parallel with confirmatory testing.  Additionally, patients who are infected with other causative infectious agents; or those who are negative, can be quickly identified and receive appropriate care or be discharged, thus making healthcare resources available to those most in need.

"Prior to the approval last month of xTAG GPP, we did not have a test that would allow us to rapidly detect a comprehensive array of disease-causing pathogens for infectious gastroenteritis," said PD Dr. Frauke Mattner, of Kliniken der Stadt, Institute of Pathology and Institute for Hygiene.  "The ability of xTAG GPP to detect not only several different types of E. coli, but also the presence of the Stx-2 gene, a key marker of this more severe STEC strain, is allowing rapid identification of patients who may be suffering from an infection of this outbreak strain. This innovative technology is an important advance and an invaluable tool in the management of the current crisis."  

"We are pleased and proud that our new innovative assay, xTAG GPP, is helping health care professionals in Germany rapidly identify patients who may be infected with this pathogen and is assisting them during this crisis," said Patrick J. Balthrop, president and CEO of Luminex.  "All of my Luminex colleagues across the globe share a serious concern for those affected and hope for a resolution to the current situation as quickly as possible."

About xTAG Gastrointestinal Pathogen Panel (GPP)

Luminex's xTAG GPP can simultaneously detect fifteen of the most common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as E. coli, Campylobacter, Salmonella and C. difficile all within 5 hours. xTAG GPP received CE mark approval in May of 2011 from European regulatory authorities and is now being used as an important aid for patient triage in the current outbreak.  

More information on Luminex and xTAG GPP can be found at , or Luminex's European office at, Krombraak 15, 4906 CR Oosterhout, The Netherlands, +

About Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene

Kliniken der Stadt Koln gGmbH is a network of urban hospitals that includes the hospitals in Cologne-Merheim and Cologne-Holweide as well as the Amsterdamer StraBe pediatric hospital. With more than 1,500 beds, the hospital group is the largest provider of inpatient health services in Cologne. Approximately 4,000 staff members treat, care for and handle about 60,000 patients per year on an inpatient basis, and more than twice as many on an outpatient basis. With annual revenues of roughly 280 million euros, the network is one of the large urban hospitals in Germany. Kliniken der Stadt Koln gGmbH is run by CEO Prof. Christian Schmidt, MD and MPH, and Roman Lovenfosse-Gehrt. Research teaching is a top priority at Kliniken der Stadt Koln gGmbH: the three urban hospitals are teaching hospitals of the University of Cologne; the hospital at Cologne-Merheim is a clinical center of the University of Witten/Herdecke.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The company's xMAP multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including genomic and proteomic research markets. The company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at  


Matt Scalo
Luminex Corporation

Mimi Torrington
Luminex Corporation

Jana Stoudemire
Porter Novelli

Hugo Beeckmans
Porter Novelli - EU
+32 (0)2 35 01 67

PD Dr. Oliver
Kliniken der Stadt Koln
Ostmerheimer Strasse 200,
51109 Koln, Cologne, Germany

PD Dr. Frauke Mattner
Kliniken der Stadt Koln
Ostmerheimer Strasse 200
51109 Koln, Cologne, Germany

SOURCE Luminex; Kliniken der Stadt Köln, Institute of Pathology and Institute for Hygiene
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From Volcano Corporation on Latest St. Jude Lawsuit
2. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
3. Pharma Elite to Unveil Latest Industry News/Program Agenda with 70+ Expert Speakers at Exclusive Event: Pharma CI Conference, September 13-14, 2011 in New Jersey
4. Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
5. LATEST Medical Introduces New Kind of Patient Information Web Site -
6. Varian Medical Systems to Exhibit the Latest Digital Image Detectors, X-Ray Tubes and Cancer Treatment Technologies at the CMEF Show in Shenzhen, China
7. NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
8. Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA
9. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
10. OVA1 Included in Latest ACOG/SGO Committee Opinion
11. MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... According to an article published November 13th on, ... D.C. revolved around the fact that proper dental care, both at-home and in the ... between periodontal disease (more commonly referred to as gum disease) and diabetes. According to ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of ... in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately ... nationally, through a vast social media strategy and across a network of top ...
(Date:11/27/2015)... ... 27, 2015 , ... Intellitec Solutions announced today that they ... Recognized as Microsoft’s official group for end users of Dynamics SL ERP software, ... industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):